Bøger i The Plenum Behavior Therapy Series serien

It is hard to put into words the initial doubts that pervaded me during my first attempt with desensitization with a seriously phobic client, as I re ligiously worked my way through the procedure: "Will this client really become relaxed?

Because the token economy literature is vast, the book encompasses programs in diverse treatment, rehabilitation, and educational settings across a wide range of populations and behaviors.

In December 1993, ISNAR, in collaboration with International Consortium for Application of Systems Approaches, organized a three-day workshop on systems approaches and modelling for agricultural development.

In the last decade, the literature of phobic and obsessive-compulsive disorders has increased enormously. Part I deals with phobic disorders and Part II with obsessive-compulsive disorders.

It is hard to put into words the initial doubts that pervaded me during my first attempt with desensitization with a seriously phobic client, as I re ligiously worked my way through the procedure: "Will this client really become relaxed?

Most of the research incorporated in this monograph was initially undertaken as part of the author's Ph.D. In addition, I would like to acknowledge the useful comments provided by Robert Avery, Shelby Stewman, Tong Hun Lee, Swarnjit Arora, and Charles Manski regarding the substance and econometric approaches used in the research.

Handbook of Effective Psydwtherapy is the culmination of 15 years of personal interest in the area of psychotherapy outcome research. and it provides an ongoing measure of how readily clinicians adapt to scientific indications in state-of-the-art care.

Handbook of Effective Psydwtherapy is the culmination of 15 years of personal interest in the area of psychotherapy outcome research. and it provides an ongoing measure of how readily clinicians adapt to scientific indications in state-of-the-art care.

Most of the research incorporated in this monograph was initially undertaken as part of the author's Ph.D. In addition, I would like to acknowledge the useful comments provided by Robert Avery, Shelby Stewman, Tong Hun Lee, Swarnjit Arora, and Charles Manski regarding the substance and econometric approaches used in the research.

One of the United States Food and Drug Administration's most difficult tasks is the assessment of risk-benefit ratios for a broad spectrum of therapeutic and prophylactic drugs.